公开(公告)号：US11957754B2

公开(公告)日：2024-04-16

申请号：US17210448

申请日：2021-03-23

Applicant: Astellas Institute for Regenerative Medicine

Inventor： Roger Gay ,  Judson Ratliff ,  Romma E. Southwick

IPC: A61K47/26 ,  A61K9/08 ,  A61K31/7004 ,  A61K31/728 ,  A61K33/06 ,  A61K33/14 ,  A61K35/28 ,  A61K35/30 ,  A61K47/02 ,  A61K47/12 ,  A61K47/36 ,  A61P27/02

CPC classification number: A61K47/26 ,  A61K9/08 ,  A61K31/7004 ,  A61K31/728 ,  A61K33/06 ,  A61K33/14 ,  A61K35/28 ,  A61K35/30 ,  A61K47/02 ,  A61K47/12 ,  A61K47/36 ,  A61P27/02 ,  A61K31/7004 ,  A61K2300/00 ,  A61K33/06 ,  A61K2300/00 ,  A61K33/14 ,  A61K2300/00 ,  A61K31/728 ,  A61K2300/00

Abstract: Some aspects of this disclosure provide clinical media that support viability, re-plating efficiency, and repopulation capacity of cells and tissues during storage for up to 48 hours or longer. The clinical media provided herein are also useful for clinical irrigation. Cell or tissue preparations comprising a cell population or tissue and a clinical medium as provided herein are also provided, as are methods for generating such preparations. Methods for using the clinical media and cell and tissue preparations provided herein, for example, for administering an effective amount of cells or tissue to a subject in need thereof, are also disclosed.

公开(公告)号：US20240082280A1

公开(公告)日：2024-03-14

申请号：US18463663

申请日：2023-09-08

Applicant: DERMAZEN, LLC

Inventor： Austin Beals

IPC: A61K31/7004 ,  A61K33/04 ,  A61K33/38 ,  A61K35/08 ,  A61K36/61 ,  A61K36/752 ,  A61K36/886

CPC classification number: A61K31/7004 ,  A61K33/04 ,  A61K33/38 ,  A61K35/08 ,  A61K36/61 ,  A61K36/752 ,  A61K36/886

Abstract: A composition for treating skin of a patient treatment. The composition has an overall weight. The composition includes a biofilm neutralizer, an antifungal, and a skin soother. The biofilm neutralizer can include one of a sugar alcohol, Xylitol, and colloidal silver. The antifungal can include one of grapefruit seed extract, sea salt, and tea tree oil. The skin soother can include one of aloe vera, methylsulfonylmethane, niacinamide, hyaluronic acid, rosemary essential oil, and urea, the oils only having a fatty acid chain length of less than C12 or greater than C24. The composition can include purified water comprising greater than approximately 50 percent of the overall weight and less than 60 percent of the overall weight.

公开(公告)号：US11918610B2

公开(公告)日：2024-03-05

申请号：US17256428

申请日：2019-06-28

Applicant: Viktor Veniaminovich Tets ,  Georgy Viktorovich Tets

Inventor： Viktor Veniaminovich Tets ,  Georgy Viktorovich Tets

IPC: A61K35/74 ,  A61K31/65 ,  A61K31/7004 ,  A61K33/06 ,  A61K35/745 ,  A61K35/747 ,  A61K35/76 ,  A61K38/08 ,  A61K38/17 ,  A61K38/46 ,  A61K39/00 ,  A61K39/108 ,  A61P3/10 ,  C07K16/12 ,  C12N15/113 ,  C12Q1/6883

CPC classification number: A61K35/74 ,  A61K31/65 ,  A61K31/7004 ,  A61K33/06 ,  A61K35/745 ,  A61K35/747 ,  A61K35/76 ,  A61K38/08 ,  A61K38/1709 ,  A61K38/465 ,  A61K39/0258 ,  A61P3/10 ,  C07K16/1232 ,  C12N15/113 ,  C12Q1/6883 ,  A61K2039/505 ,  C12N2310/14 ,  C12Q2600/118 ,  C12Q2600/156

Abstract: Methods for preventing, treating or diagnosing Type 1 Diabetes (T1D) are described. Amyloid-producing bacteria within microbiota are inactivated. Amyloid-producing bacteria are inactivated in microbiota, gastrointestinal tract, bodily fluids or tissues. Type-1 Diabetes associated microbial product production or release by microbiota is prevented. Also described is inactivation of bacteria-derived T1DAMP present in microbiota, bodily fluids or tissues of a mammal. Release of bacteria-derived T1DAMP from biofilm or bacteria to gastrointestinal tract is inhibited. Entry of bacteria-derived T1DAMP to microbiota, gastrointestinal tract, bodily fluids or tissues of a mammal is inhibited.

公开(公告)号：US20240050351A1

公开(公告)日：2024-02-15

申请号：US18496388

申请日：2023-10-27

Applicant: Mane Kancor Ingredients Private Limited

Inventor： Alain Victor Khaiat ,  Sasheendran Vijayan ,  Shaju Asokan Vaikkathukattil ,  Prakash Kumar Unnikrishnan ,  Prasobh Sivaprasad

IPC: A61K8/60 ,  A61K8/9789 ,  A61P31/00 ,  A61K8/31 ,  A61K8/34 ,  A61K31/015 ,  A61K31/045 ,  A61K31/7004 ,  A61K36/23 ,  A61K36/534 ,  A61Q5/00 ,  A61Q5/02 ,  A61K31/215 ,  A61K8/37 ,  A61K8/35 ,  A61K8/49 ,  A61K31/351 ,  A61K31/122 ,  A61K31/352 ,  A61K31/235 ,  A61K31/05 ,  A61Q17/00 ,  A61K8/92

CPC classification number: A61K8/60 ,  A61K8/9789 ,  A61P31/00 ,  A61K8/31 ,  A61K8/34 ,  A61K31/015 ,  A61K31/045 ,  A61K31/7004 ,  A61K36/23 ,  A61K36/534 ,  A61Q5/006 ,  A61Q5/02 ,  A61K8/347 ,  A61K31/215 ,  A61K8/37 ,  A61K8/35 ,  A61K8/498 ,  A61K31/351 ,  A61K31/122 ,  A61K31/352 ,  A61K31/235 ,  A61K31/05 ,  A61Q17/005 ,  A61K8/4973 ,  A61K8/922 ,  A61K2236/331 ,  A61K2800/5422 ,  A61K2800/5424 ,  A61K2800/5428 ,  A61K2800/74

Abstract: Described herein is an anti-dandruff composition including at least two anti-dandruff actives selected from a punicalagin composition; a first monoterpenoid composition, or a second monoterpenoid composition; and a dermatologically-acceptable carrier. The two or more anti-dandruff actives are present in the anti-dandruff composition in an effective amount to treat or prevent dandruff caused by the proliferation of Malassezia furfur.

公开(公告)号：US20230340479A1

公开(公告)日：2023-10-26

申请号：US18166204

申请日：2023-02-08

Applicant: City of Hope

Inventor： Marcin Tomasz Kortylewski ,  Piotr Marek Swiderski ,  Guido Marcucci ,  Bin Zhang ,  Ya-Huei Kuo

IPC: C12N15/113 ,  A61K31/7004 ,  A61K47/54 ,  A61K31/704 ,  A61K45/06 ,  C12N15/11 ,  A61K31/7125 ,  A61P35/02 ,  A61K31/506

CPC classification number: C12N15/113 ,  A61K31/7004 ,  A61K47/549 ,  A61K31/704 ,  A61K45/06 ,  C12N15/111 ,  A61K31/7125 ,  A61P35/02 ,  A61K31/506 ,  C12N2310/113 ,  C12N2310/141 ,  C12N2310/315 ,  C12N2310/3519 ,  C12N2310/17

Abstract: The present disclosure relates to a compound including a nucleic acid sequence conjugated to an anti-microRNA or a microRNA-mimic or a compound including a modified anti-microRNA sequence, compositions of such a compound, and method of treatment of a disease, and method of suppressing microRNA activity by the disclosed compound or composition.

公开(公告)号：US20230330118A1

公开(公告)日：2023-10-19

申请号：US17995919

申请日：2021-04-11

Applicant: EXPLORATION INVEST PTE LTD

Inventor： Piotr RIESKE ,  Jerzy GUBERNATOR ,  Helga KOPPER

IPC: A61K31/7004 ,  A61K31/7056 ,  A61K31/4745 ,  A61K31/4439 ,  A61K9/127 ,  A61K9/00 ,  A61P31/14 ,  A61M15/00

CPC classification number: A61K31/7004 ,  A61K31/7056 ,  A61K31/4745 ,  A61K31/4439 ,  A61K9/1277 ,  A61K9/0075 ,  A61K9/1271 ,  A61P31/14 ,  A61M15/0065

Abstract: A method of applying a substance to a human body can include providing the substance, and delivering the substance in the form of aerosol particles or powder particles to the nose or mouth of a person, wherein the particles comprise at least one active ingredient out of the group comprising ribavirin, emetine, 2-DG and NMS-873.

公开(公告)号：US20230302047A1

公开(公告)日：2023-09-28

申请号：US18124391

申请日：2023-03-21

Applicant: AMERICAN REGENT, INC

Inventor： Gopal Anyarambhatla ,  Richard Lawrence ,  Jasmina Marinkovic

IPC: A61K33/30 ,  A61K47/10 ,  A61K33/22 ,  A61K33/32 ,  A61K47/20 ,  A61K33/06 ,  A61K33/00 ,  A61K33/04 ,  A61K33/24 ,  A61K33/34 ,  A61P3/02 ,  A61K9/00 ,  A61K31/7004

CPC classification number: A61K33/30 ,  A61K9/0029 ,  A61K31/7004 ,  A61K33/00 ,  A61K33/04 ,  A61K33/06 ,  A61K33/22 ,  A61K33/24 ,  A61K33/32 ,  A61K33/34 ,  A61K47/10 ,  A61K47/20 ,  A61P3/02

Abstract: Injectable compositions that can be added to parenteral nutrition are provided. In particular, a stable injectable composition is provided which includes water, and at least one of about 800 µg to about 4,000 µg of zinc, about 40 µg to about 400 µg of copper, from about 4 µg to about 90 µg of selenium, or from about 1 µg to about 80 µg of manganese per 1 mL of the injectable composition. Methods of preparing and using of the stable injectable composition are also provided.

公开(公告)号：US11759463B2

公开(公告)日：2023-09-19

申请号：US17353558

申请日：2021-06-21

Applicant: Zensun (Shanghai) Science & Technology, Co., Ltd.

Inventor： Mingdong Zhou

IPC: A61K31/51 ,  A61P1/14 ,  A61K31/14 ,  A61K31/192 ,  A61K31/197 ,  A61K31/375 ,  A61K31/4188 ,  A61K31/4415 ,  A61K31/455 ,  A61K31/519 ,  A61K31/525 ,  A61K31/7004 ,  A61K31/714

CPC classification number: A61K31/51 ,  A61K31/14 ,  A61K31/192 ,  A61K31/197 ,  A61K31/375 ,  A61K31/4188 ,  A61K31/4415 ,  A61K31/455 ,  A61K31/519 ,  A61K31/525 ,  A61K31/7004 ,  A61K31/714 ,  A61P1/14

Abstract: Disclosed are composite compositions of B vitamins and C vitamins and the use of same in the preparation of a drug or health food for treating and/or preventing gastrointestinal conditions diseases related to deficiency of the gastrointestinal system motility. The composition comprises a vitamin B composition or an analogue or a derivative thereof and a vitamin C or an analogue or a derivative thereof.

公开(公告)号：US20230285432A1

公开(公告)日：2023-09-14

申请号：US18320462

申请日：2023-05-19

Applicant: Boehringer Ingelheim International GmbH

Inventor： Peter EICKELMANN ,  Michael MARK ,  Leo John SEMAN ,  Leo THOMAS ,  Uli Christian BROEDL ,  Rolf GREMPLER

IPC: A61K31/7048 ,  A61K31/155 ,  A61K31/00 ,  A61K31/198 ,  A61K31/341 ,  A61K31/351 ,  A61K31/39 ,  A61K31/403 ,  A61K31/4439 ,  A61K31/70 ,  A61K31/7004 ,  A61K31/7008 ,  A61K45/06 ,  A61K31/522

CPC classification number: A61K31/7048 ,  A61K31/155 ,  A61K31/00 ,  A61K31/198 ,  A61K31/341 ,  A61K31/351 ,  A61K31/39 ,  A61K31/403 ,  A61K31/4439 ,  A61K31/70 ,  A61K31/7004 ,  A61K31/7008 ,  A61K45/06 ,  A61K31/522

Abstract: The invention relates to a pharmaceutical composition comprising an SGLT2 inhibitor, a DPPIV inhibitor and a third antidiabetic agent which is suitable in the treatment or prevention of one or more conditions selected from type 1 diabetes mellitus, type 2 diabetes mellitus, impaired glucose tolerance and hyperglycemia. In addition the present invention relates to methods for preventing or treating of metabolic disorders and related conditions.

公开(公告)号：US11752246B2

公开(公告)日：2023-09-12

申请号：US17465816

申请日：2021-09-02

Applicant: Fresenius Medical Care Holdings, Inc.

Inventor： Shashikant Dattatraya Kalaskar ,  Justin Clark ,  Tao Jiang

IPC: A61M1/16 ,  A61M1/28 ,  A61K9/20 ,  A61K33/14 ,  A61K31/194 ,  A61K31/7004 ,  A61M1/36

CPC classification number: A61M1/1666 ,  A61K9/20 ,  A61K31/194 ,  A61K31/7004 ,  A61K33/14 ,  A61M1/1656 ,  A61M1/287 ,  A61M1/3627 ,  A61M2205/3306 ,  A61M2205/3317 ,  A61M2205/3368 ,  A61M2205/3553 ,  A61M2205/3584 ,  A61M2205/36 ,  A61M2205/50 ,  A61M2205/505 ,  A61M2205/52 ,  A61M2205/6072

Abstract: A dialysate mixing machine may be configured to make dialysate on demand using, among other things, a plurality of concentrates in solid tablet form. For example, a prescription may be received by the dialysate mixing machine indicating the particular chemical constituents and amounts of each chemical constituent to be included in the dialysate. Based on the prescription, the dialysate mixing machine can determine the number of tablets required for each chemical constituent (and, e.g., the required amounts of other chemical constituents that are not in tablet form). The tablets are automatically dispensed and mixed with purified water, bicarbonate, and sodium chloride in a mixing chamber to produce the dialysate according to the prescription. The dialysate mixing machine may be used with and/or coupled to a dialysis machine (e.g., a hemodialysis (HD) machine designed for home use) to provide the dialysate on demand for a dialysis treatment.